Newsroom Archives - Page 4 of 24 - Spectral Medical Inc

Spectral Medical Inc. Announces Filing of Base Shelf Prospectus

TORONTO, Canada – July 4, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has filed a preliminary short form base shelf...

Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders

TORONTO, Canada – June 6, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual Meeting of shareholders (the...

Spectral Medical to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

TORONTO, Canada – May 16, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that management will participate in a fireside chat at...

Spectral Medical Announces First Quarter and Provides Corporate Update

Tigris Trial Enrollment completed Topline results expected to be released in August 2025 Entered into an up to US$10 million Promissory Note with Vantive to Fund Spectral to PMX commercialization TORONTO, Canada – May 9, 2025 – Spectral Medical Inc. (“Spectral”...

Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive

Non-Dilutive Financing Up to US$10 Million Promissory Note Provided by Vantive If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization Company to host Corporate Update Call on May 15, 2025 TORONTO, Canada – May 7, 2025 –...

Spectral Medical Completes Tigris Trial Enrollment

157 patients enrolled Topline results expected to be released in August 2025 Company to host Corporate Update Call on May 15, 2025 TORONTO, Canada – April 16, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.